$139.41
2.74% today
Nasdaq, Nov 06, 10:00 pm CET
ISIN
US05464T1043
Symbol
AXSM

Axsome Therapeutics, Inc. Stock price

$139.41
+19.47 16.23% 1M
+27.25 24.30% 6M
+54.80 64.77% YTD
+48.44 53.25% 1Y
+82.59 145.35% 3Y
+71.95 106.66% 5Y
+130.67 1,495.08% 10Y
+130.67 1,495.08% 20Y
Nasdaq, Closing price Thu, Nov 06 2025
+3.72 2.74%
ISIN
US05464T1043
Symbol
AXSM
Industry

New AI Insights on Axsome Therapeutics, Inc. Insights AI Insights on Axsome Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$6.8b
Enterprise Value
$6.7b
Net debt
positive
Cash
$303.0m
Shares outstanding
49.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13.8 | 10.8
EV/Sales
13.6 | 10.7
EV/FCF
negative
P/B
93.6
Financial Health
Equity Ratio
10.0%
Return on Equity
-503.9%
ROCE
-77.7%
ROIC
-97.7%
Debt/Equity
2.6
Financials (TTM | estimate)
Revenue
$495.0m | $631.1m
EBITDA
$-224.9m | $-149.5m
EBIT
$-231.2m | $-169.1m
Net Income
$-246.9m | $-183.8m
Free Cash Flow
$-121.1m
Growth (TTM | estimate)
Revenue
69.8% | 63.6%
EBITDA
24.9% | 45.5%
EBIT
24.4% | 39.7%
Net Income
20.0% | 36.0%
Free Cash Flow
27.9%
Margin (TTM | estimate)
Gross
91.5%
EBITDA
-45.4% | -23.7%
EBIT
-46.7%
Net
-49.9% | -29.1%
Free Cash Flow
-24.5%
More
EPS
$-5.0
FCF per Share
$-2.4
Short interest
8.2%
Employees
683
Rev per Employee
$560.0k
Show more

Is Axsome Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Axsome Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Axsome Therapeutics, Inc. forecast:

25x Buy
96%
1x Hold
4%

Analyst Opinions

26 Analysts have issued a Axsome Therapeutics, Inc. forecast:

Buy
96%
Hold
4%

Financial data from Axsome Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
495 495
70% 70%
100%
- Direct Costs 42 42
49% 49%
9%
453 453
72% 72%
91%
- Selling and Administrative Expenses 462 462
24% 24%
93%
- Research and Development Expense 195 195
33% 33%
39%
-225 -225
25% 25%
-45%
- Depreciation and Amortization 6.37 6.37
0% 0%
1%
EBIT (Operating Income) EBIT -231 -231
24% 24%
-47%
Net Profit -247 -247
20% 20%
-50%

In millions USD.

Don't miss a Thing! We will send you all news about Axsome Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Axsome Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 10 hours ago
MIAMI, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, and its majority-owned subsidiary, Baergic Bio, Inc. (“Baergic”), today announced that Avenue has entered into an agreement for Baergic to be acquired...
Neutral
GlobeNewsWire
about 10 hours ago
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator
Positive
Seeking Alpha
one day ago
Axsome Therapeutics remains a 'Sell' due to an undifferentiated CNS pipeline, heavy SG&A, and ongoing net losses despite revenue growth. Auvelity's sales growth appears largely marketing-driven and competes in a crowded, generic-heavy depression market. AXS-05 for Alzheimer's agitation offers some promise as a non-antipsychotic, but real-world adoption and blockbuster potential are limited.
More Axsome Therapeutics, Inc. News

Company Profile

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Head office United States
CEO Herriott Tabuteau
Employees 683
Founded 2012
Website www.axsome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today